Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target. Credit: Sutro Biopharma Subscribe now Already have an account? Sign in.
